BIOMAT Database Logo BIOMAT Database Logo

Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120. 1992

Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
Second Department of Internal Medicine, Kumamoto University Medical School, Japan.

Antibodies directed against the third hypervariable loop-domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 inhibit the infection by HIV-1 in a type-specific manner without interfering with the binding of gp120 to CD4. Previous studies demonstrated that soluble CD4 (sCD4) induced the dissociation of gp120 with gp41 and caused conformational changes within the envelope oligomer. We report changes in the binding and neutralizing activity of a monoclonal antibody against the V3 loop after sCD4 binding to gp120. Flow cytometry revealed that a type-specific neutralizing monoclonal antibody against V3 loop of HTLV-IIIB, 0.5 beta, reacted with HTLV-IIIMN-infected cells after exposure to sCD4. When the sCD4-treated HTLV-IIIMN infected cells were analyzed by two-color flow cytometry, most of the CD4-bearing cells were 0.5 beta-positive, indicating that this reactivity of 0.5 beta was associated with the binding of sCD4 to the infected cells. To determine the cross-neutralization by 0.5 beta after exposure to sCD4, HTLV-IIIMN viruses pretreated with sCD4 were used to infect susceptible target cells. The addition of 0.5 beta significantly reduced the p24 antigen production (66.1 +/- 5.9 pg/ml) compared with a control murine IgG (221.3 +/- 15.3 pg/ml). In contrast, no significant reduction in the p24 antigen production was observed by adding the HTLV-IIIMN neutralizing monoclonal antibody, mu 5.5, (209.9 +/- 15.0 pg/ml). Taken together, these results suggest that sCD4/gp120 binding could induce conformational/antigenic changes within the V3 loop that result in the induction of cross-reactivity and cross-neutralizing activity of a type-specific monoclonal antibody.

UI MeSH Term Description Entries
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015699 HIV Envelope Protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. Envelope Glycoprotein gp120, HIV,HTLV-III gp120,env Protein gp120, HIV,gp120(HIV),HIV Envelope Glycoprotein gp120,gp120 Envelope Glycoprotein, HIV,HTLV III gp120,gp120, HTLV-III

Related Publications

Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity.
January 1991, Research in virology,
Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.
August 1997, Journal of virology,
Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.
November 2002, AIDS research and human retroviruses,
Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
Detecting SIV gp120 and its interaction with soluble CD4 by ELISA.
December 1993, AIDS research and human retroviruses,
Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
January 2003, Journal of virology,
Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice.
March 2020, Journal of immunology (Baltimore, Md. : 1950),
Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
Sindbis virus conformational changes induced by a neutralizing anti-E1 monoclonal antibody.
June 2008, Journal of virology,
Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).
April 1999, Immunology letters,
Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
PRODUCTION OF SPECIFIC NEUTRALIZING ANTIBODY WITH SOLUBLE ANTIGENS OF TYPE 5 ADENOVIRUS.
October 1963, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Y Maeda, and S Matsushita, and T Hattori, and T Murakami, and K Takatsuki
Neutralizing IGF-1 monoclonal antibody with cross-species reactivity.
December 1997, Hybridoma,
Copied contents to your clipboard!